ANRO241220P20000
- 0.00
- 0.000.00%
Alto Neuroscience Newsroom
Express News | Alto Neuroscience Highlights Data From Precision Psychiatry Platform At ACNP Annual Meeting; Interim Analysis For ALTO-300 Phase 2b Trial In MDD Expected Q1 2025, With Topline Results In H1 2025
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
Potential Catalysts and Strategic Focus: Analyzing Alto Neuroscience's Upcoming Trials and Precision Psychiatry Approach
Alto Neuroscience Strengthens Financial Position Amid Increased R&D
Alto Neuroscience Analyst Ratings
Stifel Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $10
Express News | Alto Neuroscience Inc : Stifel Cuts Target Price to $10 From $32
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
Alto Neuroscience Cash Position Also Expected to Fund at Least Four Additional Clinical Study Readouts >ANRO
Alto Neuroscience | 10-Q: Q3 2024 Earnings Report
Alto Neuroscience | 8-K: Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Alto Neuroscience Reports Q3 EPS (62c), Consensus (65c)
Alto Neuroscience Expects Cash Balance to Support Operations Into 2027
Express News | Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Press Release: Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Alto Neuroscience to Participate in Upcoming Investor Conferences
Notable Analyst Calls This Week: McDonald's, Apple and Enphase Energy Among Top Picks
Alto Neuroscience ANRO Phase 2b Failed; Tevogen TVGN MSFT AI Deal
Nasdaq Down 2%; US Crude Stocks Increase
Trending Stocks Today | La Rosa Holdings Surges 196.1%